Cerebral small vessel disease-related protease HtrA1 processes latent TGF-β binding protein 1 and facilitates TGF-β signaling

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 46, 2014, Pages 16496-16501

  Beaufort, Nathalie ^a   Scharrer, Eva ^a   Kremmer, Elisabeth ^b   Lux, Vanda ^c   Ehrmann, Michael ^c   Huber, Robert ^b,c,d,e,f   Houlden, Henry ^g   Werring, David ^h,i   Haffner, Christof ^a,b,c   Dichgans, Martin ^a,b,c,g  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^e Munich Center for Integrated Protein Science   (Germany)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

ⁱ Germany 3 Munich Cluster for Systems Neurology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; FIBRONECTIN; HIGH TEMPERATURE REQUIREMENT PROTEIN A1; PROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 1; UNCLASSIFIED DRUG; CONNECTIVE TISSUE GROWTH FACTOR; CTGF PROTEIN, MOUSE; HTRA1 PROTEIN, HUMAN; HYBRID PROTEIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LTBP1 PROTEIN, HUMAN; MESSENGER RNA; PROTEASE NEXIN I; PROTEIN BINDING; PRSS11 PROTEIN, MOUSE; SERINE PROTEINASE; SERPINE2 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA1;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BRAIN INFARCTION; CEREBRAL ARTERY DISEASE; CEREBRAL AUTOSOMAL RECESSIVE ARTERIOPATHY WITH SUBPATIENTS. CORTICAL INFARCTS AND LEUKOENCEPHALOPATHY; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; LEUKOENCEPHALOPATHY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; ALOPECIA; ANIMAL; BIOSYNTHESIS; BRAIN; CELL CULTURE; DEFICIENCY; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HUMAN; KNOCKOUT MOUSE; METABOLISM; MISSENSE MUTATION; PHYSIOLOGY; POINT MUTATION; PROTEIN ANALYSIS; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SKIN; SPINE DISEASE;

ALOPECIA; ANIMALS; BRAIN; CELLS, CULTURED; CEREBRAL INFARCTION; CONNECTIVE TISSUE GROWTH FACTOR; FIBROBLASTS; FIBRONECTINS; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; LATENT TGF-BETA BINDING PROTEINS; LEUKOENCEPHALOPATHIES; MICE; MICE, KNOCKOUT; MUTATION, MISSENSE; POINT MUTATION; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SERINE ENDOPEPTIDASES; SERPIN E2; SIGNAL TRANSDUCTION; SKIN; SPINAL DISEASES; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84915822450     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1418087111     Document Type: Article

References (39)

1. Wardlaw JM, Smith C, DichgansM(2013) Mechanisms of sporadic cerebral small vessel disease: Insights from neuroimaging. Lancet Neurol 12(5):483-497.
2. Dichgans M (2007) Genetics of ischaemic stroke. Lancet Neurol 6(2):149-161.
3. Federico A, et al. (2012) Hereditary cerebral small vessel diseases: A review. J Neurol Sci 322(1-2):25-30.
4. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG (2009) Cadasil. Lancet Neurol 8(7):643-653.
5. Fukutake T (2011) Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL): From discovery to gene identification. J Stroke Cerebrovasc Dis 20(2):85-93.
6. Hara K, et al. (2009) Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med 360(17):1729-1739.
7. Clausen T, Kaiser M, Huber R, Ehrmann M (2011) HTRA proteases: Regulated proteolysis in protein quality control. Nat Rev Mol Cell Biol 12(3):152-162.
8. Shiga A, et al. (2011) Cerebral small-vessel disease protein HTRA1 controls the amount of TGF-β1 via cleavage of proTGF-β1. Hum Mol Genet 20(9):1800-1810.
9. Nishimoto Y, et al. (2011) A novel mutation in the HTRA1 gene causes CARASIL without alopecia. Neurology 76(15):1353-1355.
10. Grau S, et al. (2005) Implications of the serine protease HtrA1 in amyloid precursor protein processing. Proc Natl Acad Sci USA 102(17):6021-6026.
11. Tennstaedt A, et al. (2012) Human high temperature requirement serine protease A1 (HTRA1) degrades tau protein aggregates. J Biol Chem 287(25):20931-20941.
12. Jones A, et al. (2011) Increased expression of multifunctional serine protease, HTRA1, in retinal pigment epithelium induces polypoidal choroidal vasculopathy in mice. Proc Natl Acad Sci USA 108(35):14578-14583.
13. Vierkotten S, Muether PS, Fauser S (2011) Overexpression of HTRA1 leads to ultrastructural changes in the elastic layer of Bruch's membrane via cleavage of extracellular matrix components. PLoS ONE 6(8):e22959.
14. Lehner A, et al. (2013) Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer. PLoS ONE 8(4):e60359.
15. Tiaden AN, Richards PJ (2013) The emerging roles of HTRA1 in musculoskeletal disease. Am J Pathol 182(5):1482-1488.
16. ten Dijke P, Arthur HM (2007) Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 8(11):857-869.
17. Goumans MJ, Liu Z, ten Dijke P (2009) TGF-beta signaling in vascular biology and dysfunction. Cell Res 19(1):116-127.
18. Pardali E, Goumans MJ, ten Dijke P (2010) Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol 20(9):556-567.
19. Oka C, et al. (2004) HtrA1 serine protease inhibits signaling mediated by Tgfbeta family proteins. Development 131(5):1041-1053.
20. Launay S, et al. (2008) HtrA1-dependent proteolysis of TGF-beta controls both neuronal maturation and developmental survival. Cell Death Differ 15(9):1408-1416.
21. Graham JR, et al. (2013) Serine protease HTRA1 antagonizes transforming growth factor-β signaling by cleaving its receptors and loss of HTRA1 in vivo enhances bone formation. PLoS ONE 8(9):e74094.
22. Todorovic V, Rifkin DB (2012) LTBPs, more than just an escort service. J Cell Biochem 113(2):410-418.
23. Ruiz-Ortega M, Rodríguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J (2007) TGFbeta signaling in vascular fibrosis. Cardiovasc Res 74(2):196-206.
24. Tesseur I, Zou K, Berber E, Zhang H, Wyss-Coray T (2006) Highly sensitive and specific bioassay for measuring bioactive TGF-beta. BMC Cell Biol 7:15.
25. Taipale J, Miyazono K, Heldin CH, Keski-Oja J (1994) Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol 124(1-2):171-181.
26. Ge G, Greenspan DS (2006) BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein. J Cell Biol 175(1):111-120.
27. Tatti O, Vehviläinen P, Lehti K, Keski-Oja J (2008) MT1-MMP releases latent TGF-beta1 from endothelial cell extracellular matrix via proteolytic processing of LTBP-1. Exp Cell Res 314(13):2501-2514.
28. Dallas SL, Rosser JL, Mundy GR, Bonewald LF (2002) Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 277(24):21352-21360.
29. Fontana L, et al. (2005) Fibronectin is required for integrin alphavbeta6-mediated activation of latent TGF-beta complexes containing LTBP-1. FASEB J 19(13):1798-1808.
30. Unsöld C, Hyytiäinen M, Bruckner-Tuderman L, Keski-Oja J (2001) Latent TGF-beta binding protein LTBP-1 contains three potential extracellular matrix interacting domains. J Cell Sci 114(Pt 1):187-197.
31. Dallas SL, et al. (2005) Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J Biol Chem 280(19):18871-18880.
32. Zilberberg L, et al. (2012) Specificity of latent TGF-β binding protein (LTBP) incorporation into matrix: Role of fibrillins and fibronectin. J Cell Physiol 227(12): 3828-3836.
33. An E, Sen S, Park SK, Gordish-Dressman H, Hathout Y (2010) Identification of novel substrates for the serine protease HTRA1 in the human RPE secretome. Invest Ophthalmol Vis Sci 51(7):3379-3386.
34. Horiguchi M, Ota M, Rifkin DB (2012) Matrix control of transforming growth factor-β function. J Biochem 152(4):321-329.
35. Joutel A, Faraci FM (2014) Cerebral small vessel disease: Insights and opportunities from mouse models of collagen IV-related small vessel disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke 45(4): 1215-1221.
36. Hynes RO (2009) The extracellular matrix: Not just pretty fibrils. Science 326(5957): 1216-1219.
37. Doyle JJ, Gerber EE, Dietz HC (2012) Matrix-dependent perturbation of TGFβ signaling and disease. FEBS Lett 586(14):2003-2015.
38. Thompson CS, Hakim AM (2009) Living beyond our physiological means: Small vessel disease of the brain is an expression of a systemic failure in arteriolar function: A unifying hypothesis. Stroke 40(5):e322-e330.
39. Kast J, et al. (2014) Sequestration of latent TGF-β binding protein 1 into CADASILrelated Notch3-ECD deposits. Acta Neuropathol Commun 2(1):96.